Loading…
Xencor, Inc. is projected to rise to $23.37 by 2027, a +16% move from its current price of $20.21. XNCR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $19.39 | $20.20 | $21.04 | -0.04% |
| Aug 3 | $19.06 | $20.19 | $21.39 | -0.08% |
| Aug 4 | $18.81 | $20.19 | $21.66 | -0.12% |
| Aug 5 | $18.59 | $20.18 | $21.89 | -0.16% |
| Aug 6 | $18.41 | $20.17 | $22.10 | -0.20% |
| Aug 7 | $18.24 | $20.16 | $22.28 | -0.24% |
| Aug 8 | $18.09 | $20.15 | $22.45 | -0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.09 | $20.15 | $22.45 | -0.28% |
| Week 2 | $17.25 | $20.10 | $23.41 | -0.57% |
| Week 3 | $16.62 | $20.04 | $24.16 | -0.85% |
| Week 4 | $16.10 | $19.98 | $24.80 | -1.13% |
| Week 5 | $15.65 | $19.92 | $25.37 | -1.41% |
| Week 6 | $15.25 | $19.87 | $25.89 | -1.70% |
| Week 7 | $14.89 | $19.81 | $26.37 | -1.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xencor, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company operates in the Healthcare sector and is headquartered in Pasadena, California. It was incorporated in 1997 and trades under the XNCR ticker.
The portfolio highlights include Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. These programs illustrate Xencor’s focus on antibody-based therapies across oncology and autoimmune indications.
Xencor’s core business is the discovery and development of engineered antibodies, and the company continues to advance a range of additional XmAb bispecific antibodies and related programs as part of its clinical-stage pipeline. The description reflects a healthcare company with a diversified antibody platform and a long-standing presence in the field.
Xencor, Inc. (XNCR) is a healthcare company with a current price of $20.45 and a market capitalization of $1.52B. It holds the rank of 2226 by market position in its sector. The stock exhibits bullish near-term momentum alongside a solid long-run growth expectation in the provided forecast, signaling potential upside over time.
The 30-day forecast shows the average price at $20.45 for 2026, rising to $44.89 by 2030 and up to $342.34 by 2050. The implied returns (ROI) grow from 0% in 2026 to substantial gains in later years, with a bullish sentiment prevailing in the long horizon.
In the near term, the forecast projects ongoing appreciation with higher max values in subsequent years, consistent with a broad upward trajectory across the period. This suggests a multi-year uptrend anchored by a rising average price and expanding valuation ranges.
A major floor 54.2% below — a decisive break under it would weaken the trend.
The nearest floor, 37.5% below — buyers have tended to step in here.
The nearest ceiling, 6.3% above — a clean break opens room to run.
A major ceiling 33.4% above — clearing it would confirm fresh momentum.
Key XNCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XNCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.21 | Sell | $20.20 | Buy |
| MA 10 | $19.88 | Buy | $19.49 | Buy |
| MA 20 | $17.75 | Buy | $18.15 | Buy |
| MA 50 | $14.76 | Buy | $15.85 | Buy |
| MA 100 | $13.51 | Buy | $14.46 | Buy |
| MA 200 | $13.81 | Buy | $13.70 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.74 | Neutral |
| Stoch RSI (14) | 40.57 | Neutral |
| CCI (20) | 77.02 | Neutral |
| Williams %R (14) | -19.57 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | 34.91 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 80.43 | Sell |
| TRIX (15) | 1.46 | Buy |
| Awesome (5,34) | 3.99 | Buy |
| Ultimate (7,14,28) | 64.13 | Neutral |
| Momentum (10) | 2.74 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 20.62 | Sell |
| ADX (14) | 35.97 | Buy |
| ATR (14) | 0.68 | Info |
The 30-day technical picture is bullish with momentum positive while the RSI14 sits at 80, indicating strong near-term strength. The stock is shown with a resistance at $20.45 and a support at $11.41, framing a near-term trading zone.
Prices are trading above the SMA50 of $13.47 and the SMA200 of $13.51, suggesting a constructive trend relative to these moving averages. The 30-day range spans from $15.54 to $26.90, highlighting potential volatility within the near term as prices oscillate between support and resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.41 | $20.21 | $26.19 | 0% | Neutral | |
| $17.80 | $23.37 | $32.90 | +16% | Neutral | |
| $18.73 | $25.71 | $38.15 | +27% | Bullish | |
| $22.97 | $32.74 | $50.58 | +62% | Bullish | |
| $28.95 | $42.66 | $68.14 | +111% | Bullish | |
| $35.33 | $53.68 | $88.27 | +166% | Bullish | |
| $39.70 | $62.09 | $104.77 | +207% | Bullish | |
| $35.73 | $57.44 | $99.18 | +184% | Bullish | |
| $39.02 | $64.41 | $113.61 | +219% | Bullish | |
| $46.63 | $78.96 | $142.02 | +291% | Bullish | |
| $70.56 | $134.58 | $262.47 | +566% | Bullish | |
| $147.79 | $328.43 | $718.71 | +15.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $10.41 | $20.21 | $25.20 | +0.00% |
| September 2026 | $16.54 | $19.85 | $24.71 | -1.77% |
| October 2026 | $16.05 | $19.47 | $24.62 | -1.91% |
| November 2026 | $16.49 | $20.18 | $25.83 | +3.61% |
| December 2026 | $16.41 | $20.23 | $26.19 | +0.27% |
Click any year to see its month-by-month XNCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect XNCR to range from $10.41 to $26.19 through 2026. The $20.21 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The XNCR price prediction for 2027 points to an average of $23.37 (low $17.80, high $32.90) — a potential gain of +16% on today's $20.21. A consolidation phase looks the most probable path here.
In 2028, XNCR is projected to trade between $18.73 and $38.15, averaging $25.71 — a potential gain of +27% from today's $20.21. That is up +10% on the projected 2027 average. Momentum favours further upside here.
Xencor, Inc.'s 2029 outlook centres on $32.74, within a $22.97 to $50.58 range. That is up +27% on the projected 2028 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, XNCR could reach as high as $68.14, with a base case around $42.66 and support toward $28.95 — roughly +111% from $20.21. Momentum favours further upside here.
Expect XNCR to range from $35.33 to $88.27 through 2031. The $53.68 average target implies a +166% move from current prices. That is up +26% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The XNCR price prediction for 2032 points to an average of $62.09 (low $39.70, high $104.77) — a potential gain of +207% on today's $20.21. Momentum favours further upside here.
In 2033, XNCR is projected to trade between $35.73 and $99.18, averaging $57.44 — a potential gain of +184% from today's $20.21. That is -8% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Xencor, Inc.'s 2034 outlook centres on $64.41, within a $39.02 to $113.61 range. That is up +12% on the projected 2033 average. That marks a +219% change versus current levels. Momentum favours further upside here.
By 2035, XNCR could reach as high as $142.02, with a base case around $78.96 and support toward $46.63 — roughly +291% from $20.21. Buyers look set to stay in control over this stretch.
Expect XNCR to range from $70.56 to $262.47 through 2040. The $134.58 average target implies a +566% move from current prices. That is up +70% on the projected 2035 average. Momentum favours further upside here.
The XNCR price prediction for 2050 points to an average of $328.43 (low $147.79, high $718.71) — a potential gain of +15.3x on today's $20.21. Buyers look set to stay in control over this stretch.
Investing $1,000 in XNCR today (≈ 49.480455 XNCR) could be worth
$16,250.62
+$15,250.62 (+1525%) by 2050 · US Dollar
Based on the average projected XNCR price of $328.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XNCRwould be worth at today's price.
$1,000 invested in XNCR on Jul 31, 2025 (≈ 120.192312 XNCR) would be worth
$2,429.09
+$1,429.09 (+142.9%) today · 2.43× · US Dollar
Based on a XNCR entry price of $8.32 vs. today's $20.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.44 | $1,039.61 | +4.0% |
| 1 month ago | $15.38 | $1,314.04 | +31.4% |
| 3 months ago | $12.69 | $1,592.59 | +59.3% |
| 6 months ago | $12.11 | $1,668.87 | +66.9% |
| 1 year ago | $8.32 | $2,429.09 | +142.9% |
| All time (5.0y) ago | $30.87 | $654.68 | -34.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XNCR forecast.
Our base-case forecast reaches $40.00 around 2030.
Implied market cap at $40.00: $2.97B
The multi-year forecast points to a significantly higher valuation later in the horizon, with the 2030 average price at $44.89 and an implied ROI of 119.5% alongside a bullish sentiment. By 2040, the average climbs to $141.78 with a 593.3% ROI and a bullish outlook, reflecting substantial long-run upside.
By 2050, the forecast shows an average price of $342.34 with a max of $756.00 and a min of $154.05, delivering a projected ROI of 1574% and a bullish sentiment. The trajectory includes a progression of higher max values across years, supporting a continued long-term bullish thesis while acknowledging the uncertainty inherent in forward-looking estimates.
These figures illustrate potential gains over time but are estimates, not guarantees. Actual results will depend on market conditions, execution, and external factors affecting the company and its therapies.
Tap a question to reveal the answer.
2030: min $30.27, avg $44.89, max $72.14; ROI 119.5%; sentiment BULLISH.
The forecast shows upside with rising averages and positive ROI in several years (e.g., 2029 ROI 62.1%, 2030 ROI 119.5%, 2050 ROI 1574%), but some earlier years show neutral or smaller returns (e.g., 2026 ROI 0%; 2027 ROI 17.5%). These are estimates, not guarantees.
Yes, based on the max forecast values: 2033 max $103.87, 2034 max $120.20, 2035 max $148.79, with higher later-years max values such as 2040 at $278.73 and 2050 at $756.00.
Current price is $20.45 and market capitalization is $1.52B.
2040: min $73.36, avg $141.78, max $278.73; ROI 593.3%; sentiment BULLISH. 2050: min $154.05, avg $342.34, max $756.00; ROI 1574%; sentiment BULLISH.
Xencor, Inc. Community Discussion
0Share your Xencor, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.